Menu
Revolutionising how to control the human immune and inflammatory response to disease
ABOUT US
Santersus
Santersus is an innovative Therapeutic Apheresis company focused on cleansing patient blood through the selective extra corporeal removal of neutrophil extracellular traps (NETs).
OUR TECHNOLOGY
Neutrophil Extracellular Traps (NETs)
Neutrophil Extracellular Traps (NETs) are fibers of decondensed DNA decorated with cytotoxic proteins that have been released from activated neutrophils. NETs have been recognized as one of the major driving factors in the development of sepsis, COVID-19, cancer, acute organ failure, autoimmune flares, and neurodegeneration including Alzheimer’s disease.
OUR DEVICE
NucleoCapture selective apheresis device
Santersus has developed a NucleoCapture selective apheresis device - first in class fully functional product designed to capture and remove circulating NETs from patient blood.
APPLICATIONS
Clinical applications
Recent studies have clearly demonstrated that the massive release of NETs into the systemic bloodstream plays a pivotal role in the progression of certain acute fatal and chronic debilitating conditions.
